DHR vs LH vs TMO Stock Comparison

Danaher, Labcorp Holdings and Thermo Fisher Scientific Prices as of Oct 23, 2026 Peers: Industry group
1 more company in this comparison (TECH) Create a free account to keep reading and compare up to 10 companies.
DHR Danaher Corp /De/
$230.44 +3.9% 1M +3.5% 1Y
Market cap
$164.19B
P/E
41.0x
Revenue (TTM)
$25.11B
Div. yield
–
Life Sciences Tools Healthcare
2 wins
LH Labcorp Holdings Inc.
$329.04 +8.2% 1M +15.9% 1Y
Market cap
$26.92B
P/E
26.9x
Revenue (TTM)
$14.35B
Div. yield
–
Diagnostic Labs Healthcare
6 wins

Head to Head

11 decided of 12

Labcorp Holdings leads on 6 of the 12 questions below (Labcorp Holdings 6, Thermo Fisher Scientific 3, Danaher 2). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionDHRLHTMOLeader
Larger companyMarket capitalisation $164.19B $26.92B $254.18B TMO
Cheaper on earningsLower P/E, profitable companies only 41.0x 26.9x 36.5x LH
Cheaper on forward earningsLower price / next fiscal year consensus EPS 25.5x 19.3x 26.1x LH
Faster revenue growthRevenue growth, trailing twelve months +4.6% +6.4% +7.2% TMO
More profitableNet margin, trailing twelve months 15.9% 7.0% 15.0% DHR
Better return on capitalReturn on invested capital 5.7% 8.2% 7.9% LH
Less leveragedLower net debt / EBITDA 2.9x 2.6x 3.5x LH
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months +3.5% +15.9% +17.8% TMO
Better 5-year returnAnnualised price return, 5 years -6.0%/yr +6.3%/yr +1.9%/yr LH
Less volatileAnnualised volatility, 1 year 30.6% 24.1% 29.8% LH
Higher overall scoreMean of the five percentile scores vs peers 60/100 57/100 59/100 DHR

Percentile Scorecard

DHRLHTMO

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisDHRLHTMO
Valuation 67 #75 of 228 64 #34 of 93 60 #93 of 228
Growth 20 #178 of 222 30 #62 of 88 35 #144 of 222
Profitability 88 #27 of 210 69 #28 of 87 83 #37 of 210
Financial Health 46 #131 of 241 49 #52 of 100 28 #174 of 241
Shareholder Returns 77 #32 of 138 73 #16 of 56 88 #18 of 138
Overall 60 57 59
  • DHR ranked among 248 companies in Medical Devices and Diagnostics
  • LH ranked among 103 companies in Healthcare Providers
  • TMO ranked among 248 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodDHRLHTMOSPY
1 month +3.9%+8.2%+1.2% -1.0%
3 months +20.3%+10.9%+18.6% +2.9%
6 months +30.0%+24.7%+43.5% +6.4%
Year to date +0.7%+31.2%+16.3% +11.4%
1 year +3.5%+15.9%+17.8% +13.1%
3 years +17.1%+65.6%+47.1% +79.4%
3 years, per year +5.4%+18.3%+13.7% +21.5%
5 years -26.5%+35.7%+10.1% +67.7%
5 years, per year -6.0%+6.3%+1.9% +10.9%
10 years +187.4%+176.0%+347.3% +255.2%
10 years, per year +11.1%+10.7%+16.2% +13.5%

Risk

MeasureDHRLHTMOSPY
Volatility, 1Y 30.6%24.1%29.8% 12.7%
Downside volatility, 1Y 31.7%24.1%28.3% 12.7%
Beta vs S&P 500, 1Y 0.440.320.59 1.00
Return / volatility, 1Y 0.110.660.60 1.03
Max drawdown, 5Y -50.8%-35.0%-41.5% -25.4%
From 52-week high -4.8%-3.1%-3.3% -2.5%
52-week high $242.05$339.40$696.55 $779.14
52-week low $161.91$246.64$438.34 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleDHRLHTMO
P/E now vs peer median 40.6xmedian 30.7x 26.8xmedian 25.3x 35.9xmedian 30.7x
P/S now vs peer median 6.5xmedian 3.0x 1.9xmedian 1.6x 5.4xmedian 3.0x
EV/EBITDA now vs peer median 24.0xmedian 17.7x 14.7xmedian 14.6x 25.9xmedian 17.7x
P/FCF now vs peer median 29.6xmedian 23.7x 23.0xmedian 22.7x 34.0xmedian 23.7x
P/B now vs peer median 3.1xmedian 2.4x 3.1xmedian 3.3x 4.7xmedian 2.4x
PEG now vs peer median -3.24median 0.96 2.85median 0.66 4.27median 0.96

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsDHRLHTMO
Revenue $25.11B $14.35B $46.34B
Gross profit $14.69B $4.14B $18.91B
Operating income $5.13B $1.50B $8.15B
Net income $4.00B $1.00B $6.99B
Free cash flow $5.47B $1.16B $7.32B
R&D $1.62B – $1.40B
EPS (diluted) $5.66 $12.22 $18.78
Cash & equivalents $4.35B $141.80M $4.06B
Total debt $26.56B $23.36B $42.55B
Shares (diluted) 707.60M 82.00M 371.00M
Enterprise value $148.00B $24.67B $233.20B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricDHRLHTMO
P/E 40.6x 26.8x 35.9x
P/FCF 29.6x 23.0x 34.0x
P/Operating cash flow 24.4x 16.2x 27.6x
P/S 6.5x 1.9x 5.4x
P/B 3.1x 3.1x 4.7x
P/Tangible book 5.2x 5.4x 7.3x
EV/EBITDA 24.0x 14.7x 25.9x
EV/EBIT 35.9x 21.6x 35.3x
EV/Revenue 7.3x 2.3x 6.2x
EV/FCF 33.7x 28.0x 39.3x
EV/Operating cash flow 27.8x 19.7x 31.9x
PEG (3Y EPS CAGR) -3.24 2.85 4.27

Growth

14 metrics
MetricDHRLHTMO
Revenue growth (1Y) 4.6% 6.4% 7.2%
Revenue CAGR (3Y) -0.5% 6.5% 2.1%
Gross profit growth (1Y) 2.6% 9.2% 6.2%
Gross profit CAGR (3Y) -0.9% 7.1% 3.0%
Operating income growth (1Y) 16.1% 25.6% 10.0%
Operating income CAGR (3Y) -7.1% 14.4% 6.7%
Net income growth (1Y) 17.3% 31.3% 6.2%
Net income CAGR (3Y) -14.3% 6.5% 6.9%
EPS growth (1Y) 19.2% 34.3% 7.8%
EPS CAGR (3Y) -12.5% 9.4% 8.4%
Operating cash flow growth (1Y) 7.6% -3.3% 18.9%
Operating cash flow CAGR (3Y) -7.6% 3.0% 5.4%
Free cash flow growth (1Y) 12.4% -8.4% 18.6%
Free cash flow CAGR (3Y) -9.0% 0.5% 7.7%

Profitability

14 metrics
MetricDHRLHTMO
Gross margin 58.5% 28.9% 40.8%
EBITDA margin 30.5% 15.3% 23.9%
Operating margin 20.4% 10.4% 17.6%
Pretax margin 19.0% 8.6% 16.5%
Net margin 15.9% 7.0% 15.0%
FCF margin 21.8% 8.1% 15.8%
Operating cash flow margin 26.4% 11.4% 19.5%
Return on equity 7.6% 11.6% 13.4%
Return on assets 4.5% 5.3% 6.2%
Return on invested capital 5.7% 8.2% 7.9%
Return on capital employed 6.4% 9.0% 8.3%
Asset turnover 0.3x 0.8x 0.4x
Cash conversion (OCF / net income) 1.7x 1.6x 1.3x
Stock comp / revenue 1.2% 0.9% 0.7%

Financial Health

11 metrics
MetricDHRLHTMO
Debt / assets 28.8% 31.6% 37.6%
Debt / equity 0.5x 0.7x 0.8x
Net debt / EBITDA 2.9x 2.6x 3.5x
Debt / FCF 4.9x 5.1x 5.8x
Liabilities / assets 43.1% 53.6% 53.4%
Equity / assets 56.9% 46.4% 46.6%
Interest coverage 17.6x 6.6x 5.6x
Current ratio 1.7x 1.8x 1.6x
Quick ratio 1.0x 1.2x 1.0x
Cash ratio 0.5x 0.1x 0.3x
Altman Z-score 3.70 3.42 3.98

Shareholder Returns

7 metrics
MetricDHRLHTMO
Dividend yield 0.7% 0.9% 0.3%
Net buyback yield 1.8% 2.4% 2.0%
Shareholder yield 2.5% 3.3% 2.3%
Payout ratio (earnings) – – 9.5%
Payout ratio (FCF) – – 9.0%
Dividend growth (1Y) – – 8.5%
Dividend CAGR (3Y) – – 10.8%

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusDHRLHTMO
Forward P/E 25.5xFY2026 19.3xFY2026 26.1xFY2026
EPS, next fiscal year $9.03FY2026 $17.07FY2026 $25.77FY2026
EPS growth, next FY +15.8%FY2026 +3.8%FY2026 +12.7%FY2026
EPS growth, the year after +8.9% +9.3% +1.8%
Revenue, next fiscal year $27.12BFY2026 $14.31BFY2026 $49.99BFY2026
Revenue growth, next FY +10.4%FY2026 +2.6%FY2026 +12.2%FY2026
Revenue growth, the year after -1.6% +11.9% -2.9%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersDHRLHTMO
Held by institutions 81.9% 97.0% 90.2%
Institutions holding 2,115 1,051 2,621
Change in shares held, QoQ +1.1% +1.6% +0.8%
Institutions buying 837 465 1,141
Institutions selling 1,015 393 1,144
Buyers to sellers 0.82 1.18 1.00

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

DHRLHTMO
DHR 1.00 0.45 0.72
LH 0.45 1.00 0.43
TMO 0.72 0.43 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, DHR, LH and TMO?

Thermo Fisher Scientific (TMO) is the largest by market capitalisation: Danaher (DHR) $164.19B, Labcorp Holdings (LH) $26.92B, Thermo Fisher Scientific (TMO) $254.18B.

Which stock is cheaper, DHR, LH and TMO?

Labcorp Holdings (LH) trades on the lowest price-to-earnings ratio (Danaher (DHR) 41.0x, Labcorp Holdings (LH) 26.9x, Thermo Fisher Scientific (TMO) 36.5x). On next year's consensus earnings, Labcorp Holdings (LH) is cheapest (Danaher (DHR) 25.5x, Labcorp Holdings (LH) 19.3x, Thermo Fisher Scientific (TMO) 26.1x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Thermo Fisher Scientific (TMO) grew revenue fastest over the trailing twelve months: Danaher (DHR) +4.6%, Labcorp Holdings (LH) +6.4%, Thermo Fisher Scientific (TMO) +7.2%.

Which company is more profitable?

Danaher (DHR) has the highest net margin (Danaher (DHR) 15.9%, Labcorp Holdings (LH) 7.0%, Thermo Fisher Scientific (TMO) 15.0%). On return on invested capital, Labcorp Holdings (LH) leads (Danaher (DHR) 5.7%, Labcorp Holdings (LH) 8.2%, Thermo Fisher Scientific (TMO) 7.9%).

Which stock has performed better?

Over the past year Thermo Fisher Scientific (TMO) returned the most: Danaher (DHR) +3.5%, Labcorp Holdings (LH) +15.9%, Thermo Fisher Scientific (TMO) +17.8%. Over five years, Labcorp Holdings (LH) compounded fastest (Danaher (DHR) -6.0%/yr, Labcorp Holdings (LH) +6.3%/yr, Thermo Fisher Scientific (TMO) +1.9%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Only one of these companies pays a dividend: Danaher (DHR) 0.00%, Labcorp Holdings (LH) 0.00%, Thermo Fisher Scientific (TMO) 0.00%. Danaher (DHR) and Labcorp Holdings (LH) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Labcorp Holdings (LH) has been the steadiest (Danaher (DHR) 30.6%, Labcorp Holdings (LH) 24.1%, Thermo Fisher Scientific (TMO) 29.8%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, DHR, LH and TMO?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Labcorp Holdings (LH) leads on 6. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.